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ScienceDirectA dramatic shift has occurred in how biologists use microscopy
images. Whether experiments are small-scale or high-
throughput, automatically quantifying biological properties in
images is now widespread. We see yet another revolution
under way: a transition towards using automated image
analysis to not only identify phenotypes a biologist specifically
seeks to measure (‘screening’) but also as an unbiased and
sensitive tool to capture a wide variety of subtle features of cell
(or organism) state (‘profiling’). Mapping similarities among
samples using image-based (morphological) profiling has
tremendous potential to transform drug discovery, functional
genomics, and basic biological research. Applications include
target identification, lead hopping, library enrichment,
functionally annotating genes/alleles, and identifying small
molecule modulators of gene activity and disease-specific
phenotypes.
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Introduction
Through shifts in both technology and culture, biology is
increasingly a quantitative science. Experimental meth-
ods that capture the activity or state of multiple distinct
biological processes (‘multiplexed’ assays) are thus in-
creasingly valued. The quantitative increase in the num-
ber of independent measures that can be collected in a
single assay has brought with it a qualitative change in
experimental strategies. In fact, ‘profiling’ technologies
enable measuring hundreds to thousands of distinct prop-
erties from biological samples, an approach quite distinct
from ‘screening’, which refers to traditional, targeted
experiments that seek to quantify a single process or cell
function. In this paper, we draw a distinction between
these two experimental designs: profiling vs. screening.
Profiling aims to capture and encode as many properties
of a sample as possible, while screening focuses only onCurrent Opinion in Biotechnology 2016, 39:134–142 capturing known properties of interest, usually just a few
(see Box 1).
Whereas classical biological assays might measure a partic-
ular feature of a biological sample in response to perturba-
tion (e.g., ATP consumption, cell size, or phosphorylation
state of a single protein), profiling experiments capture a
wide range of readouts and use techniques from machine
learning and data mining to identify similarities and differ-
ences among the measured patterns (sample properties).
Thus, typically, the identity of each measured feature is not
of particular importance (as in screening experiments), but
instead the discovered difference itself is the crucial read-
out. The particular measured features themselves become
relevant only when informative similarities/differences in
patterns have been identified. Profiling is a powerful ap-
proach enabling high-throughput experimentation and
multiplexed readouts to generate massive amounts of mine-
able data for use in systems biology and drug discovery.
Microscopy, followed by image processing, is one of the
few profiling methodologies suited to relatively inexpen-
sive, large-scale experiments involving hundreds of thou-
sands of tested samples. It is compatible with many scales
of biological samples: cells, tissues, or organisms (for
simplicity in this review we refer to the most common
case: cells). In image-based profiling (also known as
morphological profiling or cytological profiling [1]), large
amounts of quantitative morphological data are extracted
from microscopy images of cells to generate a profile
comprised of various measures of the shape and size of
various cellular compartments and the intensity, texture,
and colocalization of various markers (Figure 1). The goal
is to identify biologically relevant similarities and differ-
ences among samples based on these profiles using ap-
propriate computational models (see Box 2). Profiles of
biological populations can be compared to predict previ-
ously unrecognized cell states induced by different ex-
perimental perturbations of interest.
Alternate highly multiplexed assays for biological systems
include the measurement of gene expression, protein
levels, and metabolites [2,3]. While powerful, they tend
to be low-throughput to medium-throughput (hundreds
to thousands of samples per experiment) [4] and charac-
terize the average response of a population of cells (with
important exceptions: high-throughput techniques for
gene-expression are emerging [5] and RNA-seq can mea-
sure mRNA at single-cell resolution albeit currently for
only a few samples per experiment). Measuring the
response of an arrayed panel of cell lines, for example,
the NCI-60 panel, or a panel of RNAi-perturbed lines, towww.sciencedirect.com
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Box 1 High-throughput image-based screening vs. profiling.
Screening is a distinct strategy from profiling. Although both involve
large-scale (high-throughput) imaging experiments, the goals differ:
in screening, the researcher aims to measure one or more
phenotypes that are visually discernible, and choose a subset of hits
for further investigation [29]. In profiling, a broad spectrum of
measurements is captured from each sample (unguided by prior
knowledge) in order to reveal important differences and similarities
with other samples. Screening depends on a biologist’s expertise to
interrogate a particular phenomenon whereas profiling takes an
unbiased approach to grouping samples, with a higher potential to
capture unknown mechanisms.
Image-based profiling experiments remain relatively rare [30]. By
far, the most common application of high-throughput imaging is
screening large collections of small molecules in order to identify
research probes and therapeutic leads with useful biological
properties (often called high-content screening, HCS). High-content
screening is becoming more widespread in recent years, in part due
to the realization that screens based on cellular phenotypes are on
average more fruitful than higher-throughput but less physiological
screens on isolated protein targets [31,32]. High-throughput image-
based screens involve the development of assays that measure
particular morphological properties of single cells. This requires
flexible software tools for extracting measurements from images and
robust computational models for subsequent data analytics [33],
whether a single morphological feature is the basis of the screen, or
whether machine learning is used to combine multiple morphological
features in order to ‘score’ the relevant phenotype based on expert
input from biologists [34,35]. Given that image-based compound
screening is now relatively routine, we refer the reader to prior
comprehensive reviews [29,32,36–40].
Although somewhat less common, genetic perturbations are
screened in a similar manner as small molecules. The major limiting
factor is the initial construction and validation of libraries of
perturbation reagents; for completed screens to date, RNA inter-
ference is used most often but, depending on the organism,
alternatives include direct genetic manipulation (e.g., yeast deletion
strains) and overexpression libraries. For loss-of-function screens,
CRISPR-Cas9 and related technologies are an exciting prospect;
relative to RNAi these are currently thought to have lesser off-target
effects, thus improving the reliability of results [41–43].each perturbation is another form of profiling [6–9] but
requires a separate well for each measurement in the
profile and is thus not generally practical for experiments
with thousands of perturbations.
In contrast, high-content imaging techniques can mea-
sure hundreds of biologically meaningful features with
single-cell resolution in a single assay well, and can be
scaled to high-throughput assays with relative ease
(Figure 2). There is therefore significant interest in
devising appropriate computational techniques specifical-
ly for image-derived profiles, which come with technical
challenges (Box 2). There is also great potential for
combining profiles from multiple methodologies (e.g.,
imaging + gene expression) in the same experiment to
capture a broader range of cell activities.
In this review, we aim to introduce an array of applications
that can be achieved using image-based profiling, thewww.sciencedirect.com collective potential impact of which is immense. Studies
in this field are shifting from proof-of-principle to biolog-
ical discovery; their collective breadth spans research in
drug discovery and functional genomics. Microscopy is
thus moving from a qualitative assessment tool to a
powerful high-capacity quantitative modality.
We focus here on applications that involve systematically
profiling large numbers of perturbations interrogated by
microscopy imaging; outside this scope are other important
applications such as high-throughput image-based screen-
ing (Box 1), pathology applications involving human tissue
samples [10], studies of population heterogeneity [11–14],
engineering extracellular microenvironments [15–17],
location proteomics [18–22], and expression and architec-
ture mapping [23–28].
Drug discovery
Identifying mechanisms of action, targets, and toxicity
for small molecules
Small molecule perturbations can produce morphological
changes detectable by microscopy, and these changes can
reveal similarities among compounds in terms of their
phenotypic impact in a cellular context. Many studies have
demonstrated that morphological profiles can correctly
predict the mechanism of action (plus toxicity in some
cases) for blinded compounds, by grouping each unknown
compound with already-annotated compounds, based on
their phenotypic similarity [1,44,49,55–61]; several have
made novel predictions [62–65,66,67,68]. This builds on
a foundation of earlier work that identified targets based on
visual similarities, for example, the identification of the
mitotic kinesin Eg5 as the target of the small molecule
monastrol based on a distinctive monopolar spindle phe-
notype [69] and the phenotypic matching of gene-com-
pound pairs related to cytokinesis using parallel RNA
interference (RNAi) and small molecule screens [70] or
suppressor/enhancer screens for an RNAi-sensitized phe-
notype [71]. These studies often focused on oncology/cell
cycle, which is not surprising given their dramatic visual
phenotypes. A more recent study on hundreds of com-
pounds and several isogenic cell lines revealed novel gene–
drug interactions, which were also mapped using image-
based phenotypes [72]. As well, methods for identifying
individual reporter cell lines that are most useful for
grouping compounds with similar mechanisms of action
have also been developed, using phenotypic image-based
profiles [73]. Grouping compounds by their phenotypic
effects is not only feasible for static images of cells but also
for videos of complex behaviour in whole organisms; the
locomotor response of zebrafish correctly predicted many
small molecules’ mechanism of action, some previously
poorly characterized [74].
Although some studies use the term ‘screening’ when
describing the measurement of phenotypic properties of
cells, they may be referring to ‘profiling’ (e.g. [68,73]).Current Opinion in Biotechnology 2016, 39:134–142
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Image-based profiling workflow and applications. Perturbations are applied to a population of cells or organisms, and the resulting phenotypes are
observed and captured with imaging. Hundreds of morphological measurements are extracted from images, which are then analyzed using
computational models, appropriate to the target application. Those models are used to draw conclusions in a diverse range of biomedical
applications.The key distinction in these cases comes from the use of
multiple features for profiling (multivariate representa-
tions of samples), and also the unbiased analysis of
the experiments, while classical screening usually con-
siders a few phenotypes and targeted analysis of a known
phenomenon.
Lead hopping
Another application of similarity-matching among small
molecule treatments is known as lead hopping. Although
the underlying methodology is identical, the goal differs:
here, a small molecule with useful phenotypic effects but
undesirable structure is used to help identify other small
molecules with a matching phenotypic effect but with
molecular backbones better suited to medicinal chemis-
try. We have not yet seen a study using image-basedCurrent Opinion in Biotechnology 2016, 39:134–142 profiling specifically for the purpose of identifying novel
structures for further therapeutic development in a par-
ticular disease area, but the data type seems well-suited to
this task.
Small molecule library enrichment
A typical small molecule library contains significant re-
dundancy, that is, sets of small molecules with the same
effect on a molecular target or pathway. There are likely
also a large number of compounds that have no impact
whatsoever on cells. The demonstrated ability of mor-
phological profiles to group compounds with similar be-
haviour led to the hypothesis that smaller, more efficient
small molecule libraries might be selected based on
phenotypic diversity, as determined by a single profiling
assay. The first study to assess this indicates that, indeed,www.sciencedirect.com
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Box 2 Computational challenges in image-based profiling.
Morphological profiling presents many computational challenges
owing to both the size and complexity of the data. One 384-well plate
can generate more than 500 million single-cell measurements, and
an experiment might involve hundreds of plates. How to map these
raw, single-cell measurements to optimally useful perturbation
profiles is an open research question. In one comparison between
profiling techniques [44], methods that attempt to leverage popula-
tion heterogeneity were outperformed by relatively simple population
aggregation methods, highlighting the need for further research on
methods for capturing heterogeneity in profiles.
Additional complications relate to the properties of the feature space:
the measurements themselves are typically redundant, with many
features being correlated. However, given the non-linear relation-
ships between these features, simple correlation measures will not
always be sufficient to identify these associations, thereby making
feature selection non-trivial. Identifying appropriate similarity mea-
sures and dimensionality reduction methods for morphological
profiles is also an open problem [45,46]. While not unique to
morphological profiling per se, plate position effects (e.g., wells on
the edges of a plate having different characteristics than the middle
due to difference in temperature and humidity) and batch effects
introduce additional confounds that make comparing profiles across
plates or across experiments challenging [47]. At present, there are
no standard methods for addressing these problems nor are there
software packages that offer the variety of approaches that have
been proposed for each step in the workflow.
Addressing many of these problems is a high priority for labs active
in the field. Some of the most exciting computational developments
for profiling preserve single cell data and thus take into account the
increasingly well-appreciated heterogeneity of cultured cell popu-
lations [11,12,48]. For example, the Pelkmans laboratory showed
that accounting for population context of a cell (e.g. whether it lies
on the edge of a cell island, the surface area of contact with
neighbouring cells, etc.) improved the consistency between
replicate RNA interference (RNAi) screens and between siRNAs
targeting the same gene [13]. The Altschuler/Wu laboratory
identified cell subpopulations from images, measured the relative
abundance of proteins in each of these subpopulations, and
showed that grouping proteins based on this measure agreed with
known functional associations [49]. The Boutros laboratory created
morphological profiles of RNAi-induced knockdown of genes by
first identifying cell subpopulations, which in turn were used to
discover functional associations between genes [50,51]. Although
methods making sophisticated use of single-cell data have mainly
been used only in proof-of-principle studies so far, we anticipate
further development and application to real-world problems.
Image-based profiling data has always been available at single-cell
resolution, making research in this area relevant to other modalities
that have only recently become feasible to carry out at single-cell
resolution (e.g., transcription and genomics).
Finally, the use of deep learning techniques may bring interesting
benefits and solutions to some of the mentioned problems. These
methods are already common practice for solving complex
computer vision tasks [52], and are also starting to be applied in the
bioimage informatics community [53,54]. Whether applied at the
stage of segmentation, feature extraction, or classification, there is
increasing interest in adopting these methodologies to push
biological discoveries, and we expect to see more methods
incorporating these algorithms in the near future.morphological profiling can select enriched libraries with
higher rates of activity and diverse biological performance
[77].www.sciencedirect.com Functional genomics and disease
phenotyping
Characterizing genetic regulators of particular biological
processes
Image-based profiling has also been used in functional
genomics to characterize and annotate genes; the genome
is by no means fully annotated, and systematic solutions
are needed. The strategy here is to up-regulate or down-
regulate each gene’s expression and compare the pheno-
typic impact, as measured in the morphological profile, to
that of already-annotated genes.
The simplest such case begins with a high-throughput
image-based screen (Box 1) that identifies a group of ‘hit’
genes that influence a particular phenotype of interest.
Profiling can then be used to group those hits, based on
morphological similarity using a broad spectrum of image-
based phenotypes. This goes a step beyond simply cata-
loguing genetic regulators of a particular process: catego-
rization based on phenotype, using the rich morphological
data already available in the primary screen, can lend
credibility to the involvement of entire pathways in
processes and enables more efficient triaging and fol-
low-up on individual genes.
Many important cell processes have been probed using
this strategy of in-depth morphological profiling of hits
from a genetic perturbation screen. For example, the
MitoCheck project used time-lapse microscopy to track
and profile individual cells, successfully documenting and
classifying hundreds of genetic regulators associated with
mitosis [78]. Profiling has also been used to classify hits
from a screen involving membrane-trafficking activities of
endocytosis [79,80].
Functional annotation of genes by similarity
Some recent studies take a more systems biology-orient-
ed approach well beyond the above-described ‘screen,
then cluster’. Here, a large number of genes are grouped
based on similarity of morphological profiles resulting
from over-expression or under-expression of each gene.
This approach generates hypotheses for any previously
unannotated genes that closely cluster with functionally
annotated genes.
For example, early work using nonessential yeast deletion
mutants was able to group gene deletions into functional
pathways; nearly half of the mutants yielded a discernable
phenotype by imaging using a single set of three stains
(cell-surface mannoprotein, actin cytoskeleton, and nu-
clear DNA) [81]. In the presence of a perturbation (high
concentration of extracellular calcium), deletion strains
clustered into functionally related groups based on
changes in morphological features [82]. Synthetic genetic
arrays enable assaying the morphological impact of single
and double mutant yeast strains, often useful in revealing
genes involved in a process [83].Current Opinion in Biotechnology 2016, 39:134–142
138 Systems biology
Figure 2
Current Opinion in Biotechnology
Microscopy
imaging
Image analysis Morphological profiles
Ce
lls
Measurements
Morphological profiling data for a single sample. A population of U-2 OS cells was treated with rapamycin, then stained and imaged according to
the Cell Painting assay protocol [60,75] 144 hours later. Images were processed using the open-source software CellProfiler [76], yielding
1474 morphological measurements for all cells in the field of view. These data are displayed as a matrix: only a subset of the features are shown,
for 89 cells.In mammalian cells, the DNA damage/cell cycle func-
tions of the DONSON gene were identified in an unbi-
ased profiling study that grouped genes with similar loss-
of-function phenotypes using RNAi [51]. Mapping ge-
netic interactions with combinatorial RNAi is also an
effective way to uncover functional relationships between
genes, which can be measured with single-cell phenotyp-
ic readouts [84–86]. The largest map of directional epi-
static interactions has been recently built with techniques
based on large scale image analysis combined with a
statistical model that reveals novel complex dependen-
cies between genotypes and phenotypes [87].
Most of the experiments following this strategy have
used RNA interference;  it is the most common method
of genetic perturbation for mammalian cells. We do
offer a cautionary note: we recently found that morpho-
logical profiles of RNAi-induced gene knockdown are
highly sensitive and reproducible but are dominated by
so-called ‘seed effects’, a type of off-target effect [88].
There are workarounds to enrich on-target versus off-
target effects in the context of RNAi screening where a
narrow set of phenotypes are measured, but computa-
tional approaches need to be developed to enable reli-
able grouping of RNAi-induced multi-dimensional
profiles.
Grouping disease-associated genes and alleles by
functional impact
The same strategy of grouping genetic perturbations
can be applied specifically to experiments involving
overexpression of genes and alleles that have been
linked to human disease, e.g., through genome-wide
association studies. This can inform the mechanistic
understanding of the disease by placing unannotated
genes into pathways.Current Opinion in Biotechnology 2016, 39:134–142 This can also, in theory, go a step further toward person-
alized medicine by grouping disease-causing variants
based on phenotypic impact (albeit in a cell-based sys-
tem). This could ultimately guide clinical treatment in
cases where particular drug treatments are known to be
effective only for particular alleles; a previously unob-
served allele whose morphological profile is highly similar
to a known allele lends a hypothesis for an effective
treatment for that patient. We are not aware of any
published work following this approach but expect to
see examples of this strategy emerge soon.
Identifying small molecule mimics of gene signatures
(and vice versa, for target identification)
In cases where a distinctive signature has been identified
by morphological profiling of genetic perturbations, gene–
drug connections can be made by comparison of the gene’s
profile to databases of small molecules that have also been
morphologically profiled, in a strategy akin to the Connec-
tivity Map, which is based on gene expression data [89].
The strategy’s principle has been proved using imaging
data in yeast, where the targets of four drugs with known
mechanisms were re-identified by comparison of the sig-
natures induced by those small molecules to signatures
induced by yeast deletion strains [90], and where drugs
impinging on a pathway show similarity to signatures of
deletion strains in genes related to the same pathway
[91,92,93]. A similar approach using RNAi in mammalian
cells uncovered the mechanism of action of compounds
that inhibit bacterial growth via the host-pathogen inter-
face [94,95]. Although it is not trivial to compare multi-
dimensional profiles across separate experiments using
different perturbation modalities (e.g., overexpression of
genes vs. treatment with small molecules), it is tremen-
dously powerful to systematically identify small moleculeswww.sciencedirect.com
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genetic perturbations.
Identifying disease-specific phenotypes and small
molecules to revert them (signature-based screening)
The drug discovery community has increasingly recog-
nized the effectiveness of a phenotypic approach, where a
model system is sought that reflects human disease biol-
ogy as faithfully as possible [31,96–99]. The physiological
relevance of the assay system must be balanced against
compatibility for screening large chemical libraries, or at
least testing small numbers of candidate small molecules.
But what if no disease-associated phenotype is already
known? A transformative approach to creating phenotypic
model systems is to use either cell samples taken directly
from patients with disease, or cell lines manipulated to
create a genetic perturbation correlated with the disease
(some aspects of this are reviewed in [100]). The impor-
tant first step is identifying the phenotype of interest in an
unbiased way, that is, seeking a signature of the disease
state. Once the signature is known, small molecules can
be screened to identify those that revert that particular
signature back to a more wild-type-like state, hence the
term ‘signature-based screening’.
This approach was taken to first identify a cell-culture
based morphological phenotype associated with loss-of-
function of CCM2, the gene missing in patients with the
hereditary stroke syndrome cerebral cavernous malforma-
tion (CCM) [101]. The team then screened small mole-
cules and identified those that reverted the
computationally-defined image-based phenotype. Two
of those drugs proved effective in animal models of the
disease; of note, drugs chosen based on reverting the
computationally-defined phenotype performed better in
subsequent assays than drugs that reverted a human-
defined phenotype for the disease, which were tested
in parallel. Several other laboratories are taking this
promising approach, some even beginning in animal
systems. For example, ‘personalized’ Drosophila strains
carrying mutations mimicking those found in a patient’s
tumour are being used to test therapeutic cocktails, often
with a visual readout [102–104].
Conclusions
Profiling has the potential to transform many fields in
biology. We expect computational advances (Box 2) to be
an important force propelling image-based profiling forward.
With appropriate advancements, we expect image-based
profiling and analysis to be powerful tools that complement
well-established -omics methods to address challenging
questions in systems biology and drug discovery.
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